Share This Article:

Immune Augmentation of Injectable PLGA – Dextran (PLDEX) a Double Polymeric Microspheres as an Adjuvant for Hepatitis B Vaccine

Abstract Full-Text HTML Download Download as PDF (Size:191KB) PP. 104-108
DOI: 10.4236/wjv.2011.13011    3,713 Downloads   7,434 Views   Citations

ABSTRACT

A new method has been developed to prepare microspheres by blending PLGA and dextran polymers (PLDEX) using solvent evaporation technique. Recombinant hepatitis B vaccine (HBsAg) was incorporated in to the double polymeric system. The objective of this study was to investigate the feasibility of PLDEX polymeric microspheres as an adjuvant for hepatitis B vaccine (HBsAg). The present study demonstrates the immunogenicity profile of HBsAg encapsulated in PLDEX and compared their efficacy with alum adsorbed HBsAg. The single intramuscular injection of HBsAg loaded PLDEX microspheres in Wistar rats resulted satisfactory antibody titers. Based on in vivo findings PLDEX microspheres were able induce satisfactory immune response.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

S. Moni, S. Natarajapillai and M. Safhi, "Immune Augmentation of Injectable PLGA – Dextran (PLDEX) a Double Polymeric Microspheres as an Adjuvant for Hepatitis B Vaccine," World Journal of Vaccines, Vol. 1 No. 3, 2011, pp. 104-108. doi: 10.4236/wjv.2011.13011.

References

[1] M. R. Hilleman, “Vaccines in Historic Evolution and Perspective: A Narrative Vaccine Discoveries,” Vaccine, Vol. 18, No. 15, 2000, pp. 1436-1447. doi:10.1016/S0264-410X(99)00434-X
[2] M. A. Kane, “Global Status of Hepatitis B Immunization,” Lancet, Vol. 348, No. 9029, 1996, p. 696. doi:10.1016/S0140-6736(05)65598-5
[3] T. Joseph and L. Stephen, “Antiviral Chemotherapy for the Treatment of Hepatitis B Virus Infection,” Gastroenterology, Vol. 118, No. 2, 2000, pp. S83-S103. doi:10.1016/S0016-5085(00)70008-4
[4] P. R. Perrillo, W. Teresa, R. Jorge, L. Gary, S. Eugene, G. Robert, M. Paul, D. Jules, A. Paul, D. Rolland, A. Gaya, B. Steve, C. Lynn and B. Nathaniel, “A Multicenter United States—Canadian Trial to Assess Lamivudine Monotherapy before and after Liver Transplantation for Chronic Hepatitis B,” Hepatology, Vol. 33, No. 2, 2001, pp. 424-432. doi:10.1053/jhep.2001.21554
[5] L. A. Moyer and E. E. Mast, “Hepatitis B: Virology, Epidemiology, Disease, and Prevention, and an Overview of Viral Hepatitis,” American Journal of Preventive Medicine, Vol. 10, 1994, pp. 45-55.
[6] S. Tazio, K. M. Thomas, S. Gabriela and J. Pal, “Immunity in Response to Particulate Antigen Delivery Systems,” Advance Drug Delivery Revew, Vol. 57, No. 3, 2005, pp. 333-355. doi:10.1016/j.addr.2004.09.008
[7] F. U. Karen, H. Roy, Z. Kim, U. M. Christina, A. Jaklenec, J. Frazier, L. Noah, B. Paul, M. K. Alexander and L. Robert, “A Potential Approach for Decreasing the Burst Effect of Protein from PLGA Microspheres,” Journal of Pharmaceutical Sciences, Vol. 92, No. 8, 2003, pp. 1582- 1591. doi:10.1002/jps.10414
[8] I. Gutierro, R. M. Hernandez, M. Igartua, A. R. Gascon and J. L. Pedraz, “Influence of Dose and Immunization Route on the Serum IgG Antibody Response to BSA Loaded PLGA Microspheres,” Vaccine, Vol. 20, No. 17-18, 2002, pp. 2181-2190. doi:10.1016/S0264-410X(02)00146-9
[9] J. M. Alonso, K. R. Gupta, M. Caroline, R. G. Siber and L. Robert, “Biodegradable Microspheres as Controlled— Release Tetanus Toxoid Delivery Systems,” Vaccine, Vol. 12, No. 4, 1994, pp. 299-306. doi:10.1016/0264-410X(94)90092-2
[10] M. W. Russell, C. Lue, W. Van den Bake, Z. Moldoveanu and J. Mestecky, “Molecular Heterogenicity of Iga Antibodies during an Immune Response,” Clinical & Experimental Immunology, Vol. 87, No. 1, 1992, pp. 1-6. doi:10.1111/j.1365-2249.1992.tb06404.x

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.